Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 7/2019

01-07-2019 | Antipsychotics | Review Article

Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia

Authors: Mehnaz Ahmed, Marlene Malik, Johannes Teselink, Krista L. Lanctôt, Nathan Herrmann

Published in: Drugs & Aging | Issue 7/2019

Login to get access

Abstract

Behavioral and psychological symptoms associated with dementia are highly prevalent and are associated with an increased risk of institutionalization and mortality. Current pharmacological treatments for these symptoms include cholinesterase inhibitors, antipsychotics, and selective serotonin reuptake inhibitors. When used for treating behavioral and psychological symptoms associated with dementia, they are associated with limited efficacy and/or serious adverse events. As such, there has been extensive research into novel agents with varying mechanisms of action targeting behavioral and psychological symptoms associated with dementia. In this article, we present the results of a comprehensive literature search and review that evaluates current agents that have completed or are currently in clinical trials for treating behavioral and psychological symptoms associated with dementia as a primary outcome. We highlight novel agents from miscellaneous drug classes, such as dextromethorphan/quinidine, bupropion/dextromethorphan, lumateperone, deudextromethorphan/quinidine, methylphenidate and scyllo-inositol, and drugs from various therapeutic classes (including atypical antipsychotics, selective serotonin reuptake inhibitors, and cannabinoids) that have demonstrated promising results and were generally well tolerated. Future research with large appropriately powered studies using validated outcome measures for behavioral and psychological symptoms associated with dementia should be conducted to further establish the clinical utility of these agents.
Literature
1.
WHO. Dementia: a public health priority. Dementia. 2015;1–4. 
2.
Gonfrier S, Andrieu S, Renaud D, Vellas B, Robert P. Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort. J Nutr Health Aging. 2012;16(2):134–7.CrossRefPubMed
3.
4.
Devshi R, Shaw S, Elliott-King J, Hogervorst E, Hiremath A, Velayudhan L, et al. Prevalence of behavioral and psychological symptoms of dementia in individuals with learning disabilities. Diagnostics (Basel). 2015;5(4):564–76.CrossRefPubMedPubMedCentral
5.
Masopust J, Protopopová D, Vališ M, Pavelek Z, Klímová B. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review. Neuropsychiatr Dis Treat. 2018;14:1211–20.CrossRefPubMedPubMedCentral
6.
Steinberg M, Shao H, Zandi P, Lyketsos CG, Kathleen A, Norton MC, et al. In dementia: the Cache County Study. Int J Geriatr Psychiatry. 2010;23(2):170–7.CrossRef
7.
8.
Vaingankar JA, Chong SA, Abdin E, Picco L, Jeyagurunathan A, Seow E, et al. Behavioral and psychological symptoms of dementia: prevalence, symptom groups and their correlates in community-based older adults with dementia in Singapore. Int Psychogeriatrics. 2017;29(8):1363–76.CrossRef
9.
Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden? PharmacoEconomics. 2006;23:227–42.CrossRef
10.
Herrmann N, Lanctôt KL, Sambrook R, Lesnikova N, Hébert R, McCracken P, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry. 2006;21(10):972–6.CrossRefPubMed
11.
12.
Blanco-Silvente L, Castells X, Saez M, Barcelo MA, Garre-olmo J, Vilalta-Franch J, Capella D. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol. 2017;20(7):519–28.CrossRefPubMedPubMedCentral
13.
Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, Tan L. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101–9.CrossRefPubMed
14.
Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Can Fam Physician. 2014;60:433–8.
15.
Vigen CLP, Mack WJ, Keefe R, Sano M, Sultzer D, Stroup S, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831–9.CrossRefPubMedPubMedCentral
16.
Alexopoulos GS, Jeste D V, Chung H, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Postgr Med. 2005; Spec No:6-22.
17.
Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.CrossRefPubMedPubMedCentral
18.
Tran E, Dishman B. Citalopram-induced QTc prolongation: a brief review of the data. Ment Health Clin. 2012;2(6):139–41.CrossRef
19.
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA - J Am Med Assoc. 2014;311(7):682–91.CrossRef
20.
Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1). 
21.
Campanelli CM, Fick DM, Semla T, Beizer J. Potentially inappropriate medication use in older adults: the American Geriatrics Society 2012 Beers Criteria. J Am Geriatr Soc. 2012;60(4):616–31.CrossRefPubMedCentral
22.
Lai CKY. The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders. Clin Interv Aging. 2014;9:1051–61.CrossRefPubMedPubMedCentral
23.
Radloff LS. A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.CrossRef
24.
Kørner A, Lauritzen L, Abelskov K, Gulmann NC, Brodersen A-M, Wedervang-Jensen T, et al. Rating scales for depression in the elderly: external and internal validity. J Clin Psychiatry. 2007;68(3):384–9.CrossRefPubMed
25.
Helmes E, Csapo KG, Short JA. Standardization and validation of the multidimensional oberservation scale for elderly subjects (MOSES). J Gerontol. 1987;42(4):395–405.CrossRefPubMed
26.
Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):77–84.CrossRef
27.
Mega M, Carusi DA, Cummings JL, Rosenberg-Thompson S, Gornbein J, Gray K. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 2012;44(12):2308.
28.
Michael M, Cain M, Zubenko GS, Kollar M, Rosen J, Burgio L, et al. The Pittsburgh Agitation Scale: a user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry. 2009;2(1):52–9.
29.
Mohammad D, Ellis C, Rau A, Rosenberg PB, Mintzer J, Ruthirakuhan M, Herrmann N, Lanctôt KL. Psychometric properties of apathy scales in dementia: a systematic review. J Alzheimers Dis. 2018;66(3):1065–82.CrossRefPubMed
30.
31.
32.
Diefenderfer LA, Luppa C. Brexpiprazole: a review of a new treatment option for schizophrenia and major depressive disorder. Ment Health Clin. 2017;7(5):207–12.CrossRefPubMed
33.
34.
35.
36.
37.
38.
Vanover K, Dmitrienko A, Glass S, Kozauer S, Saillard J, Weingart M. Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and open-label safety switching study. Schizophr Bull. 2018;44:341.CrossRef
39.
Snyder GL, Vanover KE, Zhu H, Miller DB, O’Callaghan JP, Tomesch J, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology. 2015;232(3):605–21.CrossRefPubMed
40.
Stahl SM. Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016;21(4):271–5.CrossRefPubMed
41.
Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):211–2.CrossRef
42.
Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson’s disease. P T. 2017;42(6):368–71.PubMedPubMedCentral
43.
44.
45.
Mitchell RA, Herrmann N, Lanctôt KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer’s disease. CNS Neurosci Ther. 2011;17(5):411–27.CrossRefPubMed
46.
Herrmann N, Lanctôt KL, Eryavec G, Khan LR. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer’s disease patients. J Psychopharmacol. 2004;18(2):215–20.CrossRefPubMed
47.
Herrmann N, Lanctôt KL, Eryavec G, Van Reekum R, Khan LR. Growth hormone response to clonidine predicts aggression in Alzheimer’s disease. Psychoneuroendocrinology. 2004;29(9):1192–7.CrossRefPubMed
48.
Lanctôt KL, Herrmann N, Eryavec G, Van Reekum R, Reed K, Naranjo CA. Central serotonergic activity is related to the aggressive behaviors of Alzheimer’s disease. Neuropsychopharmacology. 2002;27(4):646–54.PubMed
49.
Lanctôt KL, Herrmann N, Van Reekum R, Eryavec G, Naranjo CA. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry. 2002;17(6):531–41.CrossRefPubMed
50.
Wilkins JM, Forester BP. Update on SSRI treatment for neuropsychiatric symptoms of dementia. Curr Psychiatry Rep. 2016;18(2):1–7.CrossRef
51.
Joubert AF, Sánchez C, Larsen F. Citalopram. Hum Psychopharmacol Clin Exp. 2000;15(6):439–45.CrossRef
52.
Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Res Pract Alzheimers Dis. 2003;7:180–6.
53.
54.
55.
56.
Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, et al. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016;3:784–92.CrossRef
57.
Wu E, Greenberg PE, Yang E, Yu A, Haim Erder M. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin. 2008;24(9):2587–95.CrossRefPubMed
58.
Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23(9):1515–9.CrossRefPubMed
59.
An H, Choi B, Park K, Kim D-H, Yang DW, Hong CH, et al. the Effect of escitalopram on mood and cognition in depressive Alzheimer’s disease subjects. Alzheimers Dement. 2016;12(7):P825.CrossRef
60.
Sherman C, Ruthirakuhan M, Vieira D, Lanctot KL, Herrmann N. Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia. Curr Opin Psychiatry. 2018;31(2):40–146.CrossRef
61.
Liu CS, Chau SA, Ruthirakuhan M, Lanctot KL, Herrmann N. Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs. 2015;29(8):615–23.CrossRefPubMed
62.
63.
Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33(2):195–209.CrossRefPubMed
64.
Tambaro S, Bortolato M. Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov. 2012;7(1):25–40.CrossRefPubMedPubMedCentral
65.
van den Elsen GA, Ahmed AI, Verkes RJ, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338–46.CrossRefPubMedPubMedCentral
66.
Shelef A, Barak Y, Berger U, et al. Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. J Alzheimers Dis. 2016;51(1):15–9.CrossRefPubMed
67.
Volicer L, Stelly M, McLaughlin J, Morris J, Volicer BJ. Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2002;12(9):913–9.CrossRef
68.
Walther S, Schupbach B, Seifritz E, Homan P, Strik W, S. W, et al. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol. 2011;31(2):256–8.
69.
Forester B, Romano C, Quayle W, Georgakas J, Rosenberg PB. Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (Ad) (Thc-Ad). Alzheimers Dement. 2017;13(7):P940.CrossRef
70.
​Lanctot K, Ruthirakuhan M, Gallagher D, Sherman C, Abraham EH, Verhoeff NPLG, Herrmann N, et al. Nabilone significantly improves agitation/aggression in patients with moderate-to-severe AD: preliminary results of a placebo-controlled, double-blind, cross-over trial. Alzheimer’s & Dementia. 2018;14(7):1385–7.CrossRef
71.
72.
73.
Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996;60(3):295–307.CrossRefPubMed
74.
Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–54.CrossRefPubMed
75.
Tung R. The development of deuterium-containing drugs. Innov Pharm Technol. 2010;32:24–8.
76.
Cummings J, Lyketsos CG, Tariot P, Peskind E, Nguyen U. Dextromethorphan/quinidine (AVP-923). Efficacy and safety for treatment of agitation in persons with Alzheimer’s disease: results from a phase 2 study (NCT01584440). 2015 AAGP Annual Meeting Peer to Peer Behavioral Activa. Am J Geriatr Psychiatry. 2015;23(3):S164–5. https://​doi.​org/​10.​1016/​j.​jagp.​2014.​12.​171.
77.
78.
Mclaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid B-Peptide and inhibit AB -induced Toxicity. J Biol Chem. 2000;275(24):18495–502.CrossRefPubMed
79.
Fenili D, Brown M, Rappaport R, McLaurin JA. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med. 2007;85(6):603–11.CrossRefPubMed
80.
Salloway S, Sperling R, Keren R, Porsteinsson AP, Van Dyck CH, Tariot PN, Crans G. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77(13):1253–62.CrossRefPubMedPubMedCentral
81.
Abushakra S, Boada Rovira M, Porsteinsson AP, Liang E, Pastrak A, Vellas B. Study of ELND005 in agitation and aggression of Alzheimer’s disease (harmony-AD): diagnostic criteria and patient characteristics. Neurodegener Dis. 2015;15(1):802.
82.
Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One. 2012;7(3):e33693.CrossRefPubMedPubMedCentral
83.
Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Med. 2012;29(6):483–90.CrossRef
84.
Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010;18(4):371–4.CrossRefPubMed
85.
Lensing SY, Sullivan DH, Ramirez D, Dennis RA, Padala PR, Bopp MM, et al. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer’s disease: a double-blind, randomized, placebo-controlled trial. Am J Psychiatry. 2017;175(2):159–68.PubMed
86.
Rosenberg PPB, Lanctot KL, Drye LT, Scherer RW, Herrmann N, Mintzer JE, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013;74(8):810–6.CrossRefPubMedPubMedCentral
87.
Ruthirakuhan M, Herrmann N, Abraham EH, Chan S, Lanctot KL. Pharmacological interventions for apathy in Alzheimer’s disease. Cochrane Database Syst Rev. 2018;5:CD012197.
88.
Scherer RW, Drye L, Mintzer J, Lanctôt K, Rosenberg P, Herrmann N, et al. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018;19(1):1–15.CrossRef
89.
Van Der Mussele S, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, et al. Behavioral syndromes in mild cognitive impairment and Alzheimer’s disease. J Alzheimer’s Dis. 2014;38(2):319–29.CrossRef
90.
Katsouri L, Vizcaychipi MP, McArthur S, Harrison I, Suárez-Calvet M, Lleo A, et al. Prazosin, an α1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer’s disease. Neurobiol Aging. 2013;34(4):1105–15.CrossRefPubMed
91.
Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, Peskind ER. Prazosin for the treatment of behavioral symptoms in Alzheimer’s disease patients with agitation and aggression. Am J Geriatr Psychiatry. 2010;17(9):744–51.CrossRef
92.
93.
94.
Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature. 2003;423(6938):435–9.
95.
Findling RL, Frazier JA, Kafantaris V, Kowatch R, McClellan J, Pavuluri M, et al. The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation. Child Adolesc Psychiatry Ment Health. 2008;2(4):1–13.
96.
97.
98.
Yu F, Zhang Y, Chuang D-M. Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma. 2012;29(13):2342–51.CrossRefPubMedPubMedCentral
99.
Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis. 2011;24(4):739–49.CrossRefPubMed
100.
Kovacsics CE, Gould TD. Shock-induced aggression in mice is modified by lithium. Pharmacol Biochem Behav. 2010;94(3):380–6.CrossRefPubMed
101.
Redrobe JP, Bourin M. The effect of lithium administration in animal models of depression: a short review. Fundam Clin Pharmacol. 1999;13(3):293–9.CrossRefPubMed
102.
Ambrósio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP, Bailly S, Pocidalo J, et al. Mechanisms of Action of Carbamazepine and Its. J Mol Biol. 2002;57(5):203–35.
103.
Al-Majed A, Bakheit AH, Alharbi RM, Abdel Aziz HA. Mirtazapine. Profiles Drug Subst Excipients Relat Methodol. 2018;43:209–54.CrossRef
104.
Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat. 2008;4(5):963–6.CrossRefPubMedPubMedCentral
105.
Lemke MR. Effect of carbamazepine on agitation and emotional lability associated with severe dementia. Eur Psychiatry. 1995;10(5):259–62.CrossRefPubMed
106.
Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54–61.CrossRefPubMed
107.
108.
109.
110.
111.
112.
Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Fredrik Jarskog L, Penn DL. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011;132(1):50–3.CrossRefPubMed
113.
Jesso S, Morlog D, Ross S, Pell MD, Pasternak SH, Mitchell DGV, Kertesz A, Finger EC. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain. 2011;134(9):2493–501.CrossRefPubMed
114.
Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, Borrie M, Wells J, Dziobek I, Pasternak S, Mitchell DGV, Rankin K, Kertesz A, Boxer A. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurol. 2015;84(2):174–81.CrossRef
Metadata
Title
Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia
Authors
Mehnaz Ahmed
Marlene Malik
Johannes Teselink
Krista L. Lanctôt
Nathan Herrmann
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2019
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00668-7

Other articles of this Issue 7/2019

Drugs & Aging 7/2019 Go to the issue

Review Article

A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn’s Disease in the Elderly Population

Original Research Article

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review

Systematic Review

Relative Risk of Adverse Events and Treatment Discontinuations Between Older and Non-Older Adults Treated with Antimuscarinics for Overactive Bladder: A Systematic Review and Meta-Analysis

Original Research Article

Rate and Outcome of Acute Kidney Injury Following Hip Fracture Surgery in Diabetic Older Patients Treated with Renin–Angiotensin–Aldosterone Antagonists

Review Article

Current Status of Bone-Forming Therapies for the Management of Osteoporosis

Current Opinion

Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits